Izervay — avacincaptad pegol
Named-patient access overview. Izervay is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Izervay
Izervay (avacincaptad pegol) is manufactured by Astellas / Iveric Bio and indicated for Geographic atrophy. It is a C5 inhibitor approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Izervay
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Izervay for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Izervay is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Izervay in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Izervay in BahrainNamed-patient access, timeline, and regulatory notes
Izervay in BangladeshNamed-patient access, timeline, and regulatory notes
Izervay in JordanNamed-patient access, timeline, and regulatory notes
Izervay in LebanonNamed-patient access, timeline, and regulatory notes
Izervay in NepalNamed-patient access, timeline, and regulatory notes
Izervay in PakistanNamed-patient access, timeline, and regulatory notes
Izervay in QatarNamed-patient access, timeline, and regulatory notes
Izervay in Saudi ArabiaNamed-patient access, timeline, and regulatory notes
Start a request for Izervay
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.